FY2025 EPS Estimates for Globus Medical, Inc. Increased by Zacks Research (NYSE:GMED)

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for shares of Globus Medical in a report issued on Monday, May 6th. Zacks Research analyst R. Department now expects that the medical device company will earn $2.89 per share for the year, up from their prior forecast of $2.88. The consensus estimate for Globus Medical’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2025 earnings at $0.67 EPS.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Tuesday, May 7th. The medical device company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.17. The business had revenue of $606.67 million for the quarter, compared to analyst estimates of $586.82 million. Globus Medical had a return on equity of 8.82% and a net margin of 7.83%. The business’s revenue was up 119.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.53 EPS.

A number of other research analysts also recently commented on the company. Royal Bank of Canada restated an “outperform” rating and set a $70.00 price objective on shares of Globus Medical in a research note on Thursday, January 11th. BTIG Research upped their price objective on Globus Medical from $60.00 to $63.00 and gave the stock a “buy” rating in a research note on Wednesday. Piper Sandler upped their price objective on Globus Medical from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Wednesday. Truist Financial upped their price objective on Globus Medical from $58.00 to $60.00 and gave the stock a “hold” rating in a research note on Wednesday, February 21st. Finally, Stifel Nicolaus raised their price target on Globus Medical from $64.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $66.60.

Globus Medical Stock Performance

GMED stock opened at $61.61 on Wednesday. The company has a current ratio of 4.88, a quick ratio of 2.72 and a debt-to-equity ratio of 0.10. The firm has a market cap of $8.34 billion, a P/E ratio of 52.66, a P/E/G ratio of 1.53 and a beta of 1.11. Globus Medical has a 12-month low of $43.38 and a 12-month high of $65.74. The stock’s 50 day simple moving average is $52.50 and its 200 day simple moving average is $51.26.

Insider Activity

In other news, Director Leslie V. Norwalk sold 10,590 shares of Globus Medical stock in a transaction on Friday, March 15th. The stock was sold at an average price of $51.99, for a total transaction of $550,574.10. Following the transaction, the director now directly owns 17,419 shares in the company, valued at approximately $905,613.81. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 24.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Globus Medical

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Globus Medical by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 11,277,722 shares of the medical device company’s stock worth $600,990,000 after buying an additional 32,220 shares during the period. Nuance Investments LLC boosted its position in shares of Globus Medical by 36.8% in the third quarter. Nuance Investments LLC now owns 3,620,518 shares of the medical device company’s stock worth $179,759,000 after buying an additional 974,693 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Globus Medical by 3.8% in the first quarter. Bank of New York Mellon Corp now owns 3,016,702 shares of the medical device company’s stock worth $161,816,000 after buying an additional 110,912 shares during the period. Wellington Management Group LLP boosted its position in shares of Globus Medical by 9.5% in the fourth quarter. Wellington Management Group LLP now owns 2,912,454 shares of the medical device company’s stock worth $155,205,000 after buying an additional 252,510 shares during the period. Finally, William Blair Investment Management LLC boosted its position in shares of Globus Medical by 1.9% in the third quarter. William Blair Investment Management LLC now owns 2,316,372 shares of the medical device company’s stock worth $115,008,000 after buying an additional 43,187 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.